Cyclophosphamide (Cyclophosphamide) Patent Expiration, LOE Window & CMS Spending

Cyclophosphamide (Cyclophosphamide) by Hikma Pharmaceuticals: FDA Orange Book LOE 2036-02-15, 5 AB generics, $11.8M 2024 CMS Part D & Medicaid spend, and $3,500 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorHikma Pharmaceuticals
FDA Application & PathwayN203856 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2036-02-15
Orange Book Patents (*PED Extensions)3 patents (0 *PED)
Active AB-Rated Generic Competitors5
2024 CMS Total Public Spend$11.8M
2024 Medicare Part D Spend$2.1M
2024 Medicaid Spend$9.7M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($3,500 intro WAC)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Hikma Pharmaceuticals across sibling Meru public-data platforms.